Sangamo Therapeutics experienced a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sangamo Therapeutics experienced a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sangamo Therapeutics
American biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksWhat Makes Sangamo (SGMO) a New Buy Stock Sangamo Therapeutics (SGMO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates --